Sofamor Danek Group, Inc. v. Gaus

61 F.3d 929, 314 U.S. App. D.C. 43, 1995 WL 457248
CourtCourt of Appeals for the D.C. Circuit
DecidedAugust 4, 1995
DocketNo. 94-5356
StatusPublished
Cited by19 cases

This text of 61 F.3d 929 (Sofamor Danek Group, Inc. v. Gaus) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sofamor Danek Group, Inc. v. Gaus, 61 F.3d 929, 314 U.S. App. D.C. 43, 1995 WL 457248 (D.C. Cir. 1995).

Opinion

Opinion for the court filed by Circuit Judge ROGERS.

ROGERS, Circuit Judge:

The court must decide whether a panel of experts and consumers convened by the Agency for Health Care Policy and Research to develop a clinical practice guideline on the treatment of lower back pain for health care practitioners was an “advisory committee” under the Federal Advisory Committee Act, 5 U.S.C.App. §§ 1-15 (“FACA”). Appellant Sofamor Danek, Inc. maintains that the Low Back Panel was an advisory committee and that the federal government must discontinue distribution of and reliance on the Clinical Practice Guideline on Acute Low Back Problems in Adults because it was not developed in compliance with FACA requirements. The district court granted summary judgment for appellees, ruling that the Low Back Panel was not a FACA advisory committee because it was not established or utilized “in the interest of obtaining advice or recommendations for ... the Federal Government.” 5 U.S.CApp. § 3(2). We affirm. 870 F.Supp. 379.

I.

The Low Back Panel was established pursuant to the Omnibus Budget Reconciliation Act of 1989, Pub.L. No. 101-239, § 6103, 103 Stat. 2106, 2189-2208 (“OBRA”). As part of OBRA, Congress created the Agency for Health Care Policy and Research (“Research Agency”).1 Congress gave the Research Agency a mandate to improve health care “through the establishment of a broad base of scientific research and through the promotion of improvements in clinical practice ... and in the organization, financing, and delivery of health care services.”2 The Research Agency is to arrange for:

the development and periodic review and updating of—
(1) clinically relevant guidelines that may be used by physicians, educators, and health care practitioners to assist in determining how diseases, disorders, and other health conditions can most effectively and [932]*932appropriately be prevented, diagnosed, treated, and managed clinically; and
(2) standards of quality, performance measures, and medical review criteria through which health care providers and other appropriate entities may assess or review the provision of health care and assure the quality of such care.[3]

To accomplish this goal, Congress authorized the Research Agency both to contract with public and private nonprofit entities and to convene panels of experts and consumers.4 When the Research Agency convenes a panel, it publicly seeks nominations and then selects the members of the panel after consultation with interested individuals and groups.5 The panel members must include physicians and health care practitioners representing varying interests, including relevant specialties, as well as two persons who do not derive their livelihood from treating the health condition addressed.6 While the Research Agency determines the health condition that the clinical practice guideline will address, the panel determines the scope and content of the guideline; neither the Research Agency nor anyone in the Department of Health and Human Services (“HHS”) can modify or disapprove the guideline developed by a panel.7 The Research Agency’s role is to support the process for development and periodic review of the guidelines,8 ensure that the panels use an evidence-based methodology,9 publish and disseminate the guidelines,10 pilot test them in a clinical setting,11 and evaluate their effect on the clinical practice of medicine.12

Pursuant to this statutory scheme, the Research Agency established a twenty-three member panel to develop a clinical practice guideline for low back disorders.13 Thereafter, the Low Back Panel held a public meeting to allow interested persons to present information orally and in writing.14 Sofamor Danek, a manufacturer of medical devices used in back surgery, declined to participate despite an invitation from the Research Agency to provide information to the Panel. The Panel ultimately developed the Clinical Practice Guideline on Acute Low Back Problems in Adults, which was published on December 8, 1994. Sofamor filed suit for declaratory and injunctive relief, and the district court granted summary judgment for appellees. Sofamor Danek appeals; our review is de novo.15

II.

Congress enacted FACA in 1976 to address problems created by the “numerous committees, boards, commissions, councils, and similar groups which have been established to advise officers and agencies in the executive branch....”16 The statute has two principal purposes: “to enhance the public accountability of advisory committees established by the Executive Branch and to [933]*933reduce wasteful expenditures on them.”17 Public Citizen v. United States Dep’t of Justice, 491 U.S. 440, 459, 109 S.Ct. 2558, 2569, 105 L.Ed.2d 377 (1989). FACA defines an advisory committee as:

any committee, board, commission, council, conference, panel, task force, or other similar group, or any subcommittee or other subgroup thereof ... which is—
(A) established by statute or reorganization plan, or
(B) established or utilized by the President, or
(C) established or utilized by one or more agencies,
in the interest of obtaining advice or recommendations for the President or one or more agencies or officers of the Federal Government... .[18]

Notwithstanding the “almost unfettered breadth” of this definition, Public Citizen, 491 U.S. at 452 n. 8, 109 S.Ct. at 2566 n. 8, Congress did not intend for FACA to apply to “every formal and informal consultation between the President or an Executive agency and a group rendering advice.” Id. at 453, 109 S.Ct. at 2566. In considering a committee of the American Bar Association, the Supreme Court had occasion to interpret narrowly the phrase “establish or utilize” to encompass only those advisory committees established by or for an agency. See id. at 462, 109 S.Ct. at 2570. In so doing the Court made clear that mere subsequent and optional use of the work product of a committee by a federal entity does not involve utilization under FACA. Id. at 452, 109 S.Ct. at 2565. The Court noted that under FACA § 2(b)(6), the work of an advisory committee is to be “exclusively advisory in nature.” Id. at 446, 109 S.Ct. at 2563.

Sofamor Danek contends that the Low Back Panel was established by OBRA and that the Clinical Practice Guideline on Acute Low Back Problems in Adults will be utilized by federal agencies and officials, including the Research Agency and the Health Care Financing Administration (“HCFA”), which administers the Medicare and Medicaid programs.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Sierra v. Romaine
Third Circuit, 2003
Natural Resources Defense Council v. Abraham
223 F. Supp. 2d 162 (District of Columbia, 2002)
Chavez-Rivas v. Olsen
207 F. Supp. 2d 326 (D. New Jersey, 2002)
Cummock, M. Victoria v. Gore, Albert
180 F.3d 282 (D.C. Circuit, 1999)
American Society of Dermatology v. Shalala
962 F. Supp. 141 (District of Columbia, 1996)
People for the Ethical Treatment of Animals, Inc. v. Barshefsky
925 F. Supp. 844 (District of Columbia, 1996)
Hernandez-Gomez v. Leonardo
917 P.2d 238 (Arizona Supreme Court, 1996)
Sofamor Danek Group, Incorporated v. Gaus
61 F.3d 929 (D.C. Circuit, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
61 F.3d 929, 314 U.S. App. D.C. 43, 1995 WL 457248, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sofamor-danek-group-inc-v-gaus-cadc-1995.